Picture of the day: digest of the main news from August 7, 2025
Main
#1 At its meetings on August 6 and 7, 2025, the Russian Ministry of Health Commission for the Formation of Drug Lists recommended including 8 new drugs in the VED list. In total, over the course of two days, the commission studied the possibility of including 23 INNs in the list. Experts, department representatives, and patients debated ravulizumab, which is used in the treatment of orphan diseases: atypical hemolytic uremic syndrome and paroxysmal nocturnal hemoglobinuria (PNH). According to clinicians' estimates, the target audience of ravulizumab could reach 10-20% of patients with PNH (according to the patient organization "Another Life", the total number of patients could reach 700 people), but the commission voted against including the drug in the list.
#2 The Russian Ministry of Health will update the standard of primary health care for adults with HIV infection, which has been in effect since 2022. The draft regulation submitted for public discussion expands the list of nosological units from two to eight positions, but at the same time reduces the list of drugs for such patients. Therapy, as now, will be carried out on an outpatient basis, the average duration of treatment for a completed case will be 365 days. In particular, the list of nosological units, if the document is adopted, will include dementia in HIV-induced disease (F02.4), laboratory detection of HIV (R75) and the presence of an HIV-induced disease in the family history (Z83.0).
Drug supply
The Expert Council of the Circle of Good has proposed adding hemophilia A to the list of diseases whose treatment is financed by the state fund. The relevant topic has been submitted for consideration to the Board of Trustees. In addition, it has been proposed to include three drugs at once in the procurement list, two of which are not registered in Russia. These are Altuvoct (efanesoctocog alfa) from Swedish Orphan Biovitrum for patients with hemophilia A and Revuforj (revumenib) from the American Syndax for the treatment of acute myeloid and acute lymphoblastic leukemia. The Expert Council also came up with an initiative to purchase the drug Opsamit (macitentan) from J&J in dispersible tablets for children with pulmonary arterial hypertension.
Pharmaceutical business
The Yuzhpharm company from the Krasnodar region will launch four generics production lines at the site in the village of Troitskaya in the Krymsky district by the end of August 2025. Investments in the project are declared at the level of 200 million rubles. The enterprise, which received a subsidy to compensate for expenses related to the manufacture of import-substituting products, is the holder of a number of registration certificates and also acts as a contract site for several pharmaceutical companies, including Alvils, Moskhimfarmpreparaty, and Vita Line.
Medical products market
The Primorsky Krai Public Procurement Center has announced an interregional offset for the localization of continuous glucose monitoring (CGM) systems production. The ten-year contract, the cost of which is set at 3.005 billion rubles, involves the purchase of more than 570 thousand CGM sets for the needs of four entities - Primorsky, Zabaikalsky and Khabarovsk Krais, Amur Oblast. In return, the investor must invest at least 400 million rubles in organizing CGM production in Primorsky Krai. An agreement between the four regions to hold a joint competition was signed in June 2025 at the St. Petersburg International Economic Forum.
Infrastructure
The Accounts Chamber of the Russian Federation reported on the results of the audit of the expenditure of budget funds for the construction of a multidisciplinary medical center at the Federal Scientific and Clinical Center of the Federal Medical and Biological Agency of Russia in Yalta, which has been under construction since 2021. The auditors revealed low efficiency in the development of federal resources - during the implementation of the project, the deadlines for commissioning the facility were postponed more than once, as of April 1, 2025, the technical readiness of the clinic was only 5.3%, and the total cost of construction increased more than twofold - from the original 15 billion to 31.8 billion rubles. The Accounts Chamber believes that this is due to the indexation of the cost of the facility for the entire construction period - until 2030.
Government support
The Russian government will allocate a subsidy from the federal budget in the amount of 177.76 million rubles for the restoration of buildings of eight medical institutions damaged during the flood in Orsk, Orenburg Region, in 2024, as well as for their additional equipment. The work will take place in branches of the Orenburg Regional Tuberculosis Dispensary and the city hospital in Orsk. Three units of medical equipment will also be delivered there - X-ray machines and a CT scanner.
Other news:
NSU opens laboratory to create reagents for CAR-T therapy
Rospotrebnadzor has developed a test for five infections at once
The Talkas sanatorium in Bashkiria is planned to be sold for 86.2 million rubles
vademec
